LLY

763.1

-0.4%↓

JNJ

176.78

+0.01%↑

ABBV

220.11

+1.65%↑

UNH

338.86

-1.15%↓

NVS

122.44

-0.51%↓

LLY

763.1

-0.4%↓

JNJ

176.78

+0.01%↑

ABBV

220.11

+1.65%↑

UNH

338.86

-1.15%↓

NVS

122.44

-0.51%↓

LLY

763.1

-0.4%↓

JNJ

176.78

+0.01%↑

ABBV

220.11

+1.65%↑

UNH

338.86

-1.15%↓

NVS

122.44

-0.51%↓

LLY

763.1

-0.4%↓

JNJ

176.78

+0.01%↑

ABBV

220.11

+1.65%↑

UNH

338.86

-1.15%↓

NVS

122.44

-0.51%↓

LLY

763.1

-0.4%↓

JNJ

176.78

+0.01%↑

ABBV

220.11

+1.65%↑

UNH

338.86

-1.15%↓

NVS

122.44

-0.51%↓

Search

Arcus Biosciences Inc

Ouvert

SecteurSoins de santé

12.16 3.49

Résumé

Variation du prix de l'action

24h

Actuel

Min

11.59

Max

12.18

Chiffres clés

By Trading Economics

Ventes

132M

160M

Employés

627

EBITDA

126M

4M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+165.11% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

240M

1.2B

Ouverture précédente

8.67

Clôture précédente

12.16

Sentiment de l'Actualité

By Acuity

50%

50%

185 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Neutral Evidence

Arcus Biosciences Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

16 sept. 2025, 17:03 UTC

Principaux Mouvements du Marché

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 sept. 2025, 16:49 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

GD Culture Shares Drop After Deal for Pallas Capital

16 sept. 2025, 16:11 UTC

Principaux Mouvements du Marché

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 sept. 2025, 23:40 UTC

Market Talk

Nikkei May Decline as Yen Strengthens -- Market Talk

16 sept. 2025, 23:34 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 sept. 2025, 23:20 UTC

Market Talk

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 sept. 2025, 21:10 UTC

Acquisitions, Fusions, Rachats

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 sept. 2025, 20:51 UTC

Market Talk

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 sept. 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

16 sept. 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Basic Materials Roundup: Market Talk

16 sept. 2025, 20:25 UTC

Résultats

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 sept. 2025, 20:24 UTC

Résultats

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 sept. 2025, 19:19 UTC

Market Talk

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 sept. 2025, 18:52 UTC

Market Talk

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 sept. 2025, 18:44 UTC

Market Talk

Global Equities Roundup: Market Talk

16 sept. 2025, 18:44 UTC

Market Talk

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 sept. 2025, 18:40 UTC

Acquisitions, Fusions, Rachats

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 sept. 2025, 18:38 UTC

Market Talk

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 sept. 2025, 18:19 UTC

Market Talk

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 sept. 2025, 18:01 UTC

Market Talk

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 sept. 2025, 17:34 UTC

Market Talk

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 sept. 2025, 16:53 UTC

Résultats

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 sept. 2025, 16:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Basic Materials Roundup: Market Talk

16 sept. 2025, 16:15 UTC

Market Talk
Acquisitions, Fusions, Rachats

Global Commodities Roundup: Market Talk

16 sept. 2025, 16:09 UTC

Market Talk
Acquisitions, Fusions, Rachats

Global Energy Roundup: Market Talk

16 sept. 2025, 16:09 UTC

Market Talk
Acquisitions, Fusions, Rachats

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 sept. 2025, 15:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 sept. 2025, 15:35 UTC

Market Talk

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 sept. 2025, 15:22 UTC

Market Talk

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 sept. 2025, 15:21 UTC

Market Talk

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Comparaison

Variation de prix

Arcus Biosciences Inc prévision

Objectif de Prix

By TipRanks

165.11% hausse

Prévisions sur 12 Mois

Moyen 30.7 USD  165.11%

Haut 52 USD

Bas 12 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

10 ratings

9

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

8.01 / 8.75Support & Résistance

Court Terme

Neutral Evidence

Moyen Terme

Neutral Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

185 / 371Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
help-icon Live chat